S1 Biopharma Inc., an early-stage biotech company developing drugs treating female sexual dysfunction, downsized its initial public offering Wednesday with the aid of Duane Morris LLP, planning to now issue 1.75 million units with warrants attached in an IPO that would raise up to $23.8 million — over a third less than previously projected.
The Patent Trial and Appeal Board has refused to allow BakerHostetler to withdraw from representing LCS Group LLC in an inter partes review proceeding brought by Shire Development LLC challenging a binge-eating disorder treatment patent, saying the patent's inventor can't represent himself.
Bill Ackman said that his Pershing Square Capital Management LP could realize $6 billion when pharmaceutical company Allergan Inc. closes its sale to rival Actavis PLC, after his pressure led to the agreement to sell last week.
Two years after the Second Circuit’s Caronia ruling gave free speech cover to off-label drug promotion, the U.S. Department of Justice has become shrewder about bringing False Claims Act cases involving dicey marketing, and imminent rulings are poised to shape the decision’s reach, experts say.
Medtronic Inc. will break off Covidien PLC’s drug-coated balloon catheter business to move forward with its $42.9 billion acquisition of the Ireland-based medical device maker, officially settling the Federal Trade Commission’s concerns that the inversion deal would be anti-competitive, according to a Monday statement.
Twenty-six companies — including two real estate investment trusts, three master limited partnerships and six private equity-backed companies — went public to raise $7.2 billion in November so far, with Latham & Watkins LLP leading the pack as counsel on eight offerings.
Novartis AG will divest its Habitrol line of nicotine patches in exchange for Federal Trade Commission approval of a joint venture with GlaxoSmithKline PLC, the FTC said Wednesday.
A Pennsylvania federal judge on Monday denied class certification to two Humana Inc. units that sued GlaxoSmithKline PLC for the cost of insuring Medicare patients harmed by its drug Avandia, saying issues of law and fact vary for proposed class members.
White & Case LLP partner Dimitrios Drivas, the chair of the firm’s global intellectual property practice group out of its New York office, won key victories for major pharmaceutical companies over the past year that helped to earn him a place on Law360's list of Life Sciences MVPs for 2014.
A California federal judge on Tuesday tossed a proposed class action claiming Merck & Co. Inc. overcharges for its Coppertone sunscreen products with sun protection factors of 55 and above, saying that the U.S. Federal Drug Administration has primary jurisdiction.
The U.S. Department of Justice’s $5.7 billion False Claims Act haul in fiscal year 2014 will further incentivize whistleblowers who share proceeds in successful suits, and the mix of companies that coughed up cash points to an expanded anti-fraud playing field, experts say. Here are five lessons from the record-smashing recoveries.
A Florida federal judge on Tuesday rejected a slew of post-trial motions lodged by attorney Mitchell J. Stein, convicted of participating in former NFL player Willie Gault's scheme to inflate heart-monitoring company Signalife Inc.'s stock, as prosecutors told the court Stein should serve 25 years in prison.
Pfizer Inc. stayed quiet on Wednesday as restrictions imposed by U.K. takeover regulators loosened, allowing it to make another run at British rival AstraZeneca PLC after a previous $118 billion takeover bid suffered a high-profile collapse earlier this year.
A group of Shire PLC shareholders accused executives at AbbVie Inc. on Wednesday of lying about the non-tax benefits behind the drugmakers' planned $55 billion union, the highest-profile inversion to crumble after the Obama administration unfurled restrictions to curb tax-motivated deals.
BT Group is in discussions with Telefonica SA concerning a potential $17 billion deal that would see BT buy back the O2 cellular network unit it sold off a decade ago, while Bayer AG is exploring the possibility of selling its diabetes device business for up to $2.49 billion.
U.K. drugmaker GlaxoSmithKline is preparing to sell €2.5 billion in notes, its first euro bonds since 2009, while Keppel DC REIT is gearing up to launch the largest IPO in Singapore in a year.
The Third Circuit on Tuesday affirmed a grant of summary judgment given to a Siemens AG subsidiary in the whistleblower suit accusing it of overcharging the U.S. Department of Veterans Affairs for medical devices, saying the district court did not abuse its discretion.
The Patent Trial and Appeal Board on Monday approved a settlement between Accord Healthcare Inc. and drugmakers Helsinn Healthcare SA and Roche Palo Alto LLC over a patent on nausea drug Aloxi, ending the second-ever post-grant review proceeding under the America Invents Act.
Novartis AG on Monday ducked a putative class action alleging it broke New Jersey consumer fraud laws by charging more for a migraine medicine than for another chemically identical painkiller when a federal judge ruled that, while strategic, the company’s pricing scheme wasn’t illegal.
A California federal judge has ruled that two patents on spinal surgery devices asserted against Alphatec Spine Inc. are invalid as indefinite, ruling that although the patents would not be invalid under an older indefiniteness standard, they are under the U.S. Supreme Court's recent Nautilus decision.
Given the Ninth Circuit decision in Harris v. Amgen Inc., practitioners should be advising their clients of a considerable change in the judiciary’s approach to the responsibilities of fiduciaries in employment plans covered by the Employee Retirement Income Security Act, says Fred Isquith of Wolf Haldenstein Adler Freeman & Herz LLP.
For pharmaceutical products, the most general form of extended patent protection available in Southeast Asia is currently data exclusivity, says James Kinnaird of Marks & Clerk.
John Doar ran the U.S. Justice Department's Civil Rights Division at perhaps the most chaotic and pivotal time in its history. His passing earlier this month is an occasion for lawyers everywhere to marvel at just how impactful one attorney can be. He didn’t just preside at a historic time, he calmly and coolly shaped it, says Kevin Curnin of the Association of Pro Bono Counsel.
Last holiday season saw some of the biggest and costliest data breaches in the retail industry’s history. With optimistic forecasts for spending this year, retailers will no doubt once again be in hackers’ crosshairs in the coming month. Implementation of data analytics — an important but sometimes underutilized tool — can assist in all phases of incident management, say economists at Edgeworth Economics LLC.
Despite the significant tilt toward technology in how litigation is now conducted, many senior lawyers still delegate tech-related issues to e-discovery specialists or associates at their firms. This is a missed opportunity not just for client development, but also for shaping the way the firm and lawyer are seen in the eyes of corporate counsel, says legal industry business development specialist Jenn Topper.
Wisconsin Pharmacal Co. LLC v. Nebraska Cultures of California Inc. is important for all manufacturers since the decision correctly found that defective components that ruin an end product are covered under a standard general liability policy, but with an important caveat — the fully integrated product must be ruined by the defective component, say attorneys at Quarles & Brady LLP.
Stockpiling of generic drugs to allow commercial introduction immediately after patent expiration is considered an act of infingement, but infringement suits contesting this conduct are almost nonexistent. The stockpiling of biologics and biosimilars, which are usually more expensive and take longer to produce than typical generics, may bring this dormant issue to the forefront, say Brian Coggio and Ron Vogel of Fish & Richardson PC.
When it heard oral argument in Louisiana Wholesale Drug Co. Inc. v. SmithKline Beecham Corp. Wednesday, the Third Circuit became the first appellate court to enter the debate regarding the impact of the U.S. Supreme Court’s decision in Actavis. This case will have a significant effect on determining which patent dispute settlements should be subject to rule of reason review under Actavis, say attorneys with Ballard Spahr LLP.
To the extent other courts adopt the New York federal court's analysis in U.S. v. Novartis Pharmaceuticals Corporation, the collateral consequence of an employee breach of internal policy or industry code of ethics and a corporate failure to appropriately sanction those employees could yield adverse consequences in the event of follow-on federal False Claims Act litigation, say attorneys with Skadden Arps Slate Meagher & Flom LLP.
Our estimates indicate that some law firms spend up to $8,000 per attorney each year on print-related costs. Although we live in a digital world, hard copy printing will remain an important part of business for years to come. Changing technology, however, offers opportunities to improve efficiencies and save money, say Senthil Rajakrishnan and Ryan Mittman of HBR Consulting LLC.